1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) OCTOBER 12, 2001
----------------
REGENERON PHARMACEUTICALS, INC.
-------------------------------------------
(Exact name of registrant as specified in its charter)
NEW YORK 0-19034 No. 13-3444607
-------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY 10591-6707
-----------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 347-7000
--------------
NOT APPLICABLE
---- ---------------
(Former name or former address, if changed since last report)
Page 1 of 5
2
INFORMATION TO BE INCLUDED IN REPORT
------------------------------------
ITEM 5. OTHER EVENTS.
On October 12, 2001, the Company issued a press release, a
copy of which is included as an exhibit to this filing.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99(a) Press Release dated October 12, 2001.
-2-
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
REGENERON PHARMACEUTICALS, INC.
By: /s/ Stuart Kolinski
------------------------------------
Stuart Kolinski
Vice President & General Counsel
Date: October 12, 2001
-3-